Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Clene (NASDAQ:CLNN) in a report published on Thursday,Benzinga reports. The firm currently has a $23.00 price target on the stock.

CLNN has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a research note on Friday, January 9th. Benchmark reissued a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Finally, UBS Group restated a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Clene currently has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Clene Stock Performance

CLNN opened at $5.92 on Thursday. The firm has a market cap of $64.23 million, a P/E ratio of -1.75 and a beta of 0.62. The business has a 50 day moving average price of $4.98 and a 200 day moving average price of $6.70. Clene has a twelve month low of $2.28 and a twelve month high of $13.50.

Insider Buying and Selling at Clene

In other news, major shareholder Chidozie Ugwumba sold 32,705 shares of Clene stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $5.50, for a total transaction of $179,877.50. Following the sale, the insider directly owned 708,587 shares in the company, valued at approximately $3,897,228.50. The trade was a 4.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David J. Matlin bought 33,333 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was acquired at an average cost of $6.50 per share, for a total transaction of $216,664.50. Following the purchase, the director owned 477,824 shares of the company’s stock, valued at $3,105,856. This trade represents a 7.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders sold 293,754 shares of company stock valued at $1,587,329. 35.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLNN. Jones Financial Companies Lllp acquired a new position in Clene during the third quarter worth $29,000. Jane Street Group LLC acquired a new stake in shares of Clene during the 2nd quarter worth about $47,000. State Street Corp lifted its holdings in Clene by 138.4% during the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after purchasing an additional 17,300 shares during the last quarter. PEAK6 LLC bought a new position in Clene during the 4th quarter valued at about $294,000. Finally, Lunt Capital Management Inc. boosted its position in Clene by 2.5% in the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after buying an additional 1,250 shares in the last quarter. Institutional investors own 23.28% of the company’s stock.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).